| ￥3500 | |
| Z05790-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
>?95%?as?determined?by?Bis?Tris?PAGE > 95%?as?determined?by?HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 20.14 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 28-38 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of RNF43, His, Human is greater than 95% as determined by SEC-HPLC. ?
RNF43, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. ?
Human R-Spondin 3, His Tag immobilized on CM5 Chip can bind RNF43, His, Human, His Tag with an affinity constant of 0.255 μM as determined in SPR assay (Biacore T200). ?
| Target Background | RNF43 (E3 ubiquitin-protein ligase RNF43 or RING-type E3 ubiquitin transferase RNF43) functions as a tumor suppressor, by exerting a predominant negative feedback mechanism in the Wnt/β-catenin signaling pathway. RNF43 inhibits Wnt/beta-catenin signaling by ubiquitinating Frizzled receptor and targeting it to the lysosomal pathway for degradation. |
| Synonyms | E3 ubiquitin-protein ligase RNF43;RING finger protein 43;RING-type E3 ubiquitin transferase RNF43;RNF43 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
